Login / Signup

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.

Bruce Ac CreeBaldur MagnussonNicolas RouyrreRobert J FoxGavin GiovannoniPatrick VermerschAmit Bar-OrRalf GoldDaniela Piani MeierGöril KarlssonDavorka TomicChristian WolfFrank DahlkeLudwig Kappos
Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)
By controlling the confounding impact of on-study relapses on confirmed disability progression, these statistical approaches provide a methodological framework to assess treatment effects on disability progression in relapsing and non-relapsing patients. The analyses support that siponimod may be useful for treating secondary progressive multiple sclerosis in patients with or without relapses.
Keyphrases
  • multiple sclerosis
  • white matter
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • rheumatoid arthritis
  • patient reported
  • disease activity